X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare SUVEN LIFE with Orchid Chemicals - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SUVEN LIFE vs ORCHID PHARMA LTD - Comparison Results

ORCHID PHARMA LTD 
   Change

Orchid Chemicals & Pharmaceuticals Ltd. (Orchid) is today a globally recognized, integrated pharmaceutical company with core competencies in the development and manufacture of Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms as well... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SUVEN LIFE ORCHID PHARMA LTD SUVEN LIFE/
ORCHID PHARMA LTD
 
P/E (TTM) x 19.4 -0.2 - View Chart
P/BV x 4.2 0.2 2,656.8% View Chart
Dividend Yield % 0.5 0.0 -  

Financials

 SUVEN LIFE   ORCHID PHARMA LTD
EQUITY SHARE DATA
    SUVEN LIFE
Mar-18
ORCHID PHARMA LTD
Sep-13
SUVEN LIFE/
ORCHID PHARMA LTD
5-Yr Chart
Click to enlarge
High Rs251194 129.3%   
Low Rs15535 442.9%   
Sales per share (Unadj.) Rs49.1276.5 17.8%  
Earnings per share (Unadj.) Rs9.7-79.2 -12.3%  
Cash flow per share (Unadj.) Rs11.4-43.5 -26.2%  
Dividends per share (Unadj.) Rs1.500-  
Dividend yield (eoy) %0.70-  
Book value per share (Unadj.) Rs60.353.9 111.8%  
Shares outstanding (eoy) m127.2870.45 180.7%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x4.10.4 997.3%   
Avg P/E ratio x20.9-1.4 -1,444.4%  
P/CF ratio (eoy) x17.8-2.6 -675.9%  
Price / Book Value ratio x3.42.1 158.5%  
Dividend payout %15.40-   
Avg Mkt Cap Rs m25,8258,067 320.2%   
No. of employees `0001.12.8 38.3%   
Total wages/salary Rs m6132,527 24.2%   
Avg. sales/employee Rs Th5,832.66,956.1 83.8%   
Avg. wages/employee Rs Th571.5902.5 63.3%   
Avg. net profit/employee Rs Th1,153.8-1,993.0 -57.9%   
INCOME DATA
Net Sales Rs m6,25319,477 32.1%  
Other income Rs m233407 57.1%   
Total revenues Rs m6,48519,884 32.6%   
Gross profit Rs m1,9821,103 179.7%  
Depreciation Rs m2132,519 8.5%   
Interest Rs m465,227 0.9%   
Profit before tax Rs m1,955-6,236 -31.4%   
Minority Interest Rs m020 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0511 0.0%   
Tax Rs m718-125 -573.7%   
Profit after tax Rs m1,237-5,580 -22.2%  
Gross profit margin %31.75.7 559.9%  
Effective tax rate %36.72.0 1,829.9%   
Net profit margin %19.8-28.7 -69.0%  
BALANCE SHEET DATA
Current assets Rs m5,62211,014 51.0%   
Current liabilities Rs m1,16832,060 3.6%   
Net working cap to sales %71.2-108.1 -65.9%  
Current ratio x4.80.3 1,401.6%  
Inventory Days Days8195 85.8%  
Debtors Days Days3634 107.1%  
Net fixed assets Rs m3,32529,440 11.3%   
Share capital Rs m127705 18.1%   
"Free" reserves Rs m7,5472,043 369.5%   
Net worth Rs m7,6743,800 202.0%   
Long term debt Rs m149,018 0.2%   
Total assets Rs m9,13546,510 19.6%  
Interest coverage x43.2-0.2 -22,383.4%   
Debt to equity ratio x02.4 0.1%  
Sales to assets ratio x0.70.4 163.4%   
Return on assets %14.0-0.8 -1,848.1%  
Return on equity %16.1-146.9 -11.0%  
Return on capital %26.0-3.7 -697.1%  
Exports to sales %037.9 0.0%   
Imports to sales %022.6 0.0%   
Exports (fob) Rs mNA7,378 0.0%   
Imports (cif) Rs mNA4,406 0.0%   
Fx inflow Rs m5,0667,513 67.4%   
Fx outflow Rs m2,0015,649 35.4%   
Net fx Rs m3,0651,865 164.4%   
CASH FLOW
From Operations Rs m6991,682 41.6%  
From Investments Rs m-6-9,860 0.1%  
From Financial Activity Rs m-5776,644 -8.7%  
Net Cashflow Rs m116-1,535 -7.6%  

Share Holding

Indian Promoters % 63.4 32.3 196.3%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.0 4.6 -  
FIIs % 0.0 3.3 -  
ADR/GDR % 0.0 4.6 -  
Free float % 36.5 55.3 66.0%  
Shareholders   37,287 84,811 44.0%  
Pledged promoter(s) holding % 0.0 54.9 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SUVEN LIFE With:   CIPLA  PFIZER  NATCO PHARMA  SUN PHARMA  PIRAMAL ENTERPRISES  

Compare SUVEN LIFE With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices End Marginally Lower; FMCG & IT Stocks Witness Losses(Closing)

After opening the day on a positive note today, Indian share markets witnessed losses thereafter and ended their trading session marginally lower.

Related Views on News

SUVEN LIFE Surges by 5%; BSE HEALTHCARE Index Up 1.3% (Market Updates)

Sep 26, 2018 | Updated on Sep 26, 2018

SUVEN LIFE share price has surged by 5% and its current market price is Rs 289. The BSE HEALTHCARE is up by 1.3%. The top gainers in the BSE HEALTHCARE Index is SUVEN LIFE (up 5.3%). The top losers are PIRAMAL ENTERPRISES (down 0.2%) and FORTIS HEALTHCARE (down 0.5%).

ORCHID PHARMA LTD Announces Quarterly Results (4QFY18); Net Profit Up 50.8% (Quarterly Result Update)

Aug 24, 2018 | Updated on Aug 24, 2018

For the quarter ended March 2018, ORCHID PHARMA LTD has posted a net profit of Rs 924 m (up 50.8% YoY). Sales on the other hand came in at Rs 2 bn (down 24.0% YoY). Read on for a complete analysis of ORCHID PHARMA LTD's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

My First Pharma Stock Recommendation!(The 5 Minute Wrapup)

Sep 21, 2018

This company has not only created a niche in the pharma space, it has done so profitably.

Oh Yes! This is the Best Trading Opportunity in Two Decades(Profit Hunter)

Sep 21, 2018

Getting ready to buy stocks once this correction is over? This private sector bank should be on a profit hunter's radar.

Outperformance of Strong Established Brands in the Indian Stock market(Chart Of The Day)

Sep 14, 2018

Strong Well established Indian Brands have comfortably outperformed the index in the decade post the global financial crisis.

How IL&FS Rating Downgrade Will Impact Your Mutual Funds...(Outside View)

Sep 17, 2018

PersonalFN explains the impact of IL&FS rating downgrade on mutual funds.

How To Identify Sachin Tendulkars And Rahul Dravids Of Tomorrow For Your Mutual Fund Portfolio(Outside View)

Sep 19, 2018

PersonalFN explains how to pick 'undiscovered' or lesser-known mutual funds that are capable of generating big gains for you.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

SUVEN LIFE SHARE PRICE


Sep 26, 2018 (Close)

TRACK SUVEN LIFE

  • Track your investment in SUVEN LIFE with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SUVEN LIFE 8-QTR ANALYSIS

COMPARE SUVEN LIFE WITH

MARKET STATS